

# Active substances set

**Search phrase:** belantamab mafodotin

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Multiple myeloma and plasma cell neoplasms

| | | |
|---|---|---|
| **Belantamab mafodotin** | Belantamab mafodotin is indicated in adults for the treatment of relapsed or refractory multiple myeloma: • in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and • in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide. | FULL REIMBURSEMENT<br>ESMO |